On February 25, 2025, ADM announced its agreement with Japanese company Asahi Group Foods Corporation to exclusively market and distribute Asahi Group’s proprietary postbiotic, Lactobacillus gasseri CP2305. This ingredient targets stress, mood and sleep support.
“Stress mood and sleep are among the fastest-growing wellness segments and - as the cornerstone to physical and emotional health - they are also some of the most disruptive factors to everyday life and overall well-being if not properly supported,” said Mark Lotsch, ADM’s president of global health and wellness. “Our agreement with pioneering Asahi Group to bring science-backed Lactobacillus gasseri CP2305 postbiotic into our robust health and wellness solutions library is a critical step in advancing new product development to support consumers’ quality of line around the world.”
L. gasseri CP2305 is a postbiotic ingredient developed from lactic acid bacteria. It has been tested in eight human clinical trials, which showed evidence of reduced stress, better sleep efficiency, improved sleep quality and improved sleep duration.
With this agreement, Asahi group will continue to use the ingredient in supplements and beverages sold in Japan, while ADM will expand the ingredient’s distribution to food manufacturers in North America, Europe and Asia.
“Asahi is committed to solving global food and health challenges, especially those contributing to mental and physical wellbeing for consumers,” said Kazuhiro Hayashi, corporate officer and senior general manager at Asahi Group Foods. “We’re excited to enter a supply agreement with ADM for Lactobacillus gasseri CP2305, leveraging their expertise in microbiology and global scale to effectively expand the reach of this innovative solution.”
